A5013056953- Pharmaceutical Practices and Patient Outcomes
- Blood Pressure and Hypertension Studies
- Antibiotic Use and Resistance
- COVID-19 Clinical Research Studies
- Sodium Intake and Health
- Pharmaceutical Economics and Policy
- CAR-T cell therapy research
- Acute Kidney Injury Research
- Health Systems, Economic Evaluations, Quality of Life
- Pancreatic and Hepatic Oncology Research
- Blood groups and transfusion
- Pharmaceutical studies and practices
- Cardiac, Anesthesia and Surgical Outcomes
- Hormonal Regulation and Hypertension
- Attention Deficit Hyperactivity Disorder
- Pneumonia and Respiratory Infections
- Diabetes and associated disorders
- Integrated Circuits and Semiconductor Failure Analysis
- Urinary Tract Infections Management
- Cardiac Health and Mental Health
- Periodontal Regeneration and Treatments
- Biosimilars and Bioanalytical Methods
- Liver Disease Diagnosis and Treatment
- Bacterial Identification and Susceptibility Testing
- Migraine and Headache Studies
Navarre Institute of Health Research
2018-2024
Servicio Navarro de Salud
2018-2024
Clinica Universidad de Navarra
2015-2019
Objective The FOURIER trial showed a benefit of the PCSK9 inhibitor evolocumab over placebo with respect to cardiovascular outcomes in patients disease. However, we observed some inconsistencies between information Clinical Study Report (CSR) and that 2017 primary results publication. We aimed restore mortality data based on contained death narratives CSR. Methods Mortality publication were compared In cases discrepancy sources, an independent committee blindly readjudicated restored cause...
Using 4 data-sources (Spain, Italy, United Kingdom) data and a 1:1 matched cohort study, we aimed to estimate vaccine effectiveness (VE) in preventing SARS-CoV-2 infections with hospitalisations (±30 days) death (±56 general population clinical subgroups homologous/heterologous booster schedules (Comirnaty-BNT Spikevax-MOD original COVID-19 vaccines) by comparison unboosted individuals, during Delta beginning of Omicron variants. Hazard Ratio (HR, Cox models) VE ([1-HR]*100) were calculated...
<ns4:p>Objective To determine the efficacy and safety of CAR-T therapy in treatment patients with hematologic malignancies, comparison other current therapies. Design A living systematic review Methods We will include randomized trials evaluating effect versus active treatments, hematopoietic stem cell transplantation, best supportive care or any intervention malignancies. Non-randomized primary studies be searched case we found no direct evidence from controlled trials. Two reviewers...
A randomized clinical trial assessing plasma rich in growth factors (PRGF) versus hyaluronic acid for knee osteoarthritis was published 2012 (sponsor ID BTI-01-EC/07/ART). Evidence of misreporting discovered following access to unpublished materials. In accordance with the principles Restoring Invisible and Abandoned Trials (RIAT) initiative, we sought re-analyse Study PRGF based on materials.Reanalysis made possible primarily two study documents (original protocol final report) obtained...
Concomitant use of diuretics, renin-angiotensin-aldosterone system (RAAS) inhibitors, and non-steroidal anti-inflammatory drugs (NSAIDs) or metamizole, known as 'triple whammy' (TW), has been associated with an increased risk acute kidney injury (AKI). Nevertheless, there is still uncertainty on its impact in hospitalisation mortality. The aim the study was to analyse association between exposure TW for AKI, all-cause mortality need renal replacement therapy (RRT).